The ribonuclease l-dependent antiviral roles of human 2′,5′-oligoadenylate synthetase family members against hepatitis C virus  by Kwon, Young-Chan et al.
FEBS Letters 587 (2013) 156–164journal homepage: www.FEBSLetters .orgThe ribonuclease L-dependent antiviral roles of human
20,50-oligoadenylate synthetase family members against hepatitis C virus0014-5793/$36.00  2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2012.11.010
⇑ Corresponding author. Fax: +82 2 923 9923.
E-mail address: ahnbyung@korea.ac.kr (B.-Y. Ahn).Young-Chan Kwon a, Ju-Il Kang a, Soon B. Hwang b, Byung-Yoon Ahn a,⇑
a School of Life Sciences and Biotechnology, Korea University, Anam-dong 5-1, Seoul 136-701, Republic of Korea
b Ilsong Institute of Life Science, Hallym University, Gwanyang-dong 1605-4, Anyang 431-060, Republic of Korea
a r t i c l e i n f o a b s t r a c tArticle history:
Received 16 October 2012
Accepted 9 November 2012
Available online 26 November 2012





Antiviral proteinThe latent ribonuclease RNase L and the interferon-inducible 20,50-oligoadenylate synthetase (OAS)
have been implicated in the antiviral response against hepatitis C virus (HCV). However, the speciﬁc
roles of these enzymes against HCV have not been fully elucidated. In this study, a scarce endoge-
nous expression and RNA degrading activity of RNase L in human hepatoma Huh7 cells enabled
us to demonstrate the antiviral activity of RNase L against HCV replication through the transient
expression of the enzyme. The antiviral potential of speciﬁc members of the OAS family was further
examined through overexpression and RNA interference approaches. Our data suggested that
among the members of the OAS family, OAS1 p46 and OAS3 p100 mediate the RNase L-dependent
antiviral activity against HCV.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
RNase L is a latent ribonuclease that is expressed constitutively
and ubiquitously in almost all mammalian cells. The binding of
20,50-linked oligoadenylate (2–5A) to the N-terminal ankyrin re-
peats of RNase L induces the dimerization of the enzyme and the
activation of its endonuclease activity. Activated RNase L cleaves
viral and cellular RNAs at single-stranded regions, resulting in the
inhibition of the translation and replication of viral RNA [1]. In addi-
tion to the direct antiviral effect of RNase L, an indirect antiviral role
for this enzyme has been suggested; in particular, it has been
hypothesized that the small RNA fragments that are generated by
RNase L can act as a signal for interferon (IFN) production [2].
The structurally unique 2–5A, which is a speciﬁc activator of
RNase L, is synthesized through the oligomerization of ATP, which
is catalyzed by the 20,50-oligoadenylate synthetases (OASs).
Although the transcription of the OAS gene is induced by IFNs,
OAS proteins are translated as latent enzymes before they are acti-
vated by the binding of dsRNA; this dsRNA is likely of viral origin.
Thus, OAS in combination with RNase L constitutes an essential
antiviral pathway that is induced in response to IFN [3].
Hepatitis C virus (HCV) is a hepatotrophic member of the ﬂavi-
viruses that possesses a positive-strand RNA genome [4]. HCV-in-
fected individuals typically develop persistent infections thatoften lead to chronic infection, cirrhosis and hepatocellular carci-
noma. It is estimated that 170 million individuals around the world
are currently infected with HCV. Type I IFN in combination with
ribavirin and one of the two recently approved protease inhibitors
is the current standard therapy for chronic hepatitis C [5].
RNase L and OAS have been implicated in the antiviral response
against HCV. The two proteins were found to be abundant in the
liver tissues of patients with chronic hepatitis C, and they co-local-
ized with HCV NS5A protein, suggesting that they are likely en-
gaged in antagonizing interactions with HCV [6]. It has been
found that OAS transcripts are induced in the liver of HCV patients
and model animals [7,8]. HCV patients undergoing IFN therapy
demonstrated an elevated level of OAS in sera; this increase in
OAS was correlated with predicted virological responses in one
study [9], but they were uncorrelated in another study [10].
Despite the strong implications that RNase L and OAS play a role
in the response to HCV infection, their speciﬁc roles against HCV
have not yet been elucidated. The cleavage of the HCV genome
RNA by RNase L has been demonstrated in vitro [11]. The RNase
L-mediated cleavage products of transfected HCV RNA triggered
IFN producing signals, suggesting an indirect antiviral role of RNase
L against HCV [6]. Recently, RNase L was identiﬁed along with sev-
eral cellular IFN-stimulated proteins as antiviral proteins that re-
strict HCV replicons through an RNAi-based knock-down
screening approach [12]. In this study, we demonstrated the anti-
viral activity of RNase L against HCV replication in human hepa-
toma Huh7 cells through transient expression of the enzyme. Our
data further suggested that two members of the OAS family,
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ral activity against HCV infection.
2. Materials and methods
2.1. Cells and viruses
Human hepatoma Huh7 and Huh7.5 cells were grown in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) that had been supple-
mented with 50 lg/ml of gentamicin and 5% fetal bovine serum
(Hyclone) at 37 C in an atmosphere containing 5% CO2. HepG2
cells were cultured in the aforementioned medium that had been
supplemented with 10% FBS. Human lung epithelial carcinoma
A549 cells were maintained in RPMI 1640 medium that had been
supplemented with 10% FBS. HCV replicon cells were prepared
by the electroporation of RNA from the genotype 2a HCV strains
of JFH-1 [13], J6/JFH-1 [14] or SGR/Luc-JFH1 with a Gene Pulser II
RF module (Bio-Rad) in accordance with previously described pro-
cedures [15]. The viral RNA genome was synthesized in vitro from
appropriate templates with the MEGAscript T7 Kit (Ambion). Virus
titer in the culture supernatant was determined in the focus-form-
ing assay in accordance with previously characterized procedures
[16]. As described below, viral replication was assessed by immu-
noblotting, northern blotting or RT-PCR analyses. The luciferase
activity for SGR/Luc-JFH1 was measured with the Luciferase Assay
System (Promega). The recombinant Newcastle disease virus
rNDV-GFP was described in the published literature [17]. Sendai
virus was grown in eggs and titrated by a hemagglutination assay.
2.2. Plasmid construction and transfection
The cDNA for human RNase L, OAS1 isoforms p42, p48 and p52,
OAS2 isoforms p69 and p71, and OAS3 p100 were ampliﬁed from
the RNA of A549 cells following IFN-a treatment. OAS1 p46 cDNA
was prepared from human HT1080 ﬁbrosarcoma cells. The RT-PCR
was conducted using the ImProm II RT-PCR system (Promega) with
oligo(dT) and the speciﬁc primers shown in the Supplementary Ta-
ble 1. The PCR products were digested with HindIII–BamHI (for
RNase L) or NotI-XbaI (for OAS1 isoforms) and were then subcloned
into p3Flag-CMV10 (Sigma). Ampliﬁed OAS2 and OAS3 cDNAs
were subcloned into pHM6 (Roche). The nuclease-defective RNase
L constructs, R667A, H672A and R462Qwere generated by PCRwith
primers shown in Table 1. To construct SGR/Luc-JFH1, the neomycin
resistancegeneof pSGR-JFH1 [18]was replacedwith theﬁreﬂy lucif-
erase gene from pGL3-Basic (Promega) in accordance with previ-
ously described procedures [19]. Lipofectamine 2000 (Invitrogen)
was used for the transfection of cells with DNA constructs and poly-
ribo(I:C) (Sigma). The siRNAs (GenePharma, sequences shown in Ta-
ble 1) were co-transfected with JFH-1 RNA by electroporation.
2.3. RNA analyses
To examine the rRNA cleavage, cellular RNA was prepared with
RNAisoPLUS (Takara) and separated in 1.5% agarose gel containing
formaldehyde. HCV RNA was analyzed either by northern blotting
that was performed in accordance with previously described meth-
ods [15] or by quantitative real-time PCR. For the qPCR ampliﬁca-
tions, the ImProm RT-PCR system (Promega) was used to reverse
transcribe the HCV RNA, and the MyiQ Real-Time PCR system (Bio-
Rad Laboratories) was used to conduct the subsequent ampliﬁcation
with HCV-speciﬁc primers (Table 1) under the following conditions:
3 min at 95 C, followed by 40 cycles of 95 C for 30 s, 55 C for 30 s
and 72 C for 30 s. The melting curve was obtained through 81 cy-
cles; these cycles were each 10 s in length with temperature incre-
ments of 0.5 C within 55–95 C. The resulting data were analyzed
with the iQ5optical systemsoftwarepackage (Bio-RadLaboratories).2.4. The immunoblotting and immunoﬂuorescence assays
For immunoblotting, cells were lysed in RIPA buffer (10 mM
Tris–HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100,
0.1% SDS, 0.25% sodium deoxycholate, and 1 mM PMSF). The pro-
teins were separated in a denaturating polyacrylamide gel and
transferred onto nitrocellulose membranes (Hybond ECL; GE
Healthcare). The blots were incubated with primary and secondary
antibodies that had been diluted in TBST buffer (10 mM Tris–HCl
[pH 7.6], 150 mM NaCl, 0.1% Tween 20) containing 5% skim milk
and were visualized with PicoWest SuperSignal ECL reagents
(Pierce). Polyclonal antibodies to NS5A and MxA were raised in
accordance with previously described procedures [15]. The anti-
RNase L antibody that was used was purchased from Invitrogen.
The anti-tubulin antibody that was used was purchased from Ap-
plied Biological Materials. The anti-Flag and anti-HA antibodies
were purchased from Sigma, and the anti-core antibody was pur-
chased from Pierce.
For immunostaining, cells were ﬁxed with 3.7% paraformalde-
hyde in PHEM buffer (60 mM Pipes, 25 mM HEPES, 10 mM EGTA,
2 mM MgSO4, pH 7.0), permeabilized for 10 min in PBS with 0.5%
Triton X-100, and incubated for 10 min in blocking buffer (PBS con-
taining 1% BSA and 0.1% Tween 20). The cells were incubated for
1 h at room temperature with a 1:1,000 dilution of primary anti-
bodies in blocking buffer, washed with PBS and incubated for 1 h
at room temperature in blocking buffer with a 1:1,000 dilution of
FITC-conjugated sheep anti-mouse IgG (F-3008, Sigma) or Alexa
Fluor 568 goat-rabbit IgG (Invitrogen Molecular Probes). The cells
were stained with 1 lg/ml DAPI in PBS for 1 min, washed with PBS,
and mounted on a slide glass with FluoroGuard antifade reagent
(Bio-Rad). Images were obtained with a confocal laser scanning
microscope (LSM 700, Carl Zeiss).3. Results
3.1. The scarce endogenous expression of RNase L in human hepatoma
cells
Before investigating the antiviral activity of RNase L against
HCV, we examined the expression of RNase L in the human hepa-
toma Huh7 cell line and its subclone Huh7.5, both of which sup-
port HCV replication. Although RNase L (a 80 kDa protein) was
detected in our immunoblot of the human lung carcinoma A549
cell line, it was not detected in Huh7, Huh7.5 or another human
hepatoma cell line, HepG2 (Fig. 1A). The RNase L expression in
A549 cells appeared to be unaffected by IFN-a treatment, whereas
the IFN-inducible protein MxA was markedly induced in all four of
the cell lines that we examined. Consistent with the observed
expression patterns for RNase L, the speciﬁc cleavage of rRNAs,
the characteristic feature of activated RNase L [20], was observed
in the agarose gel electrophoresis of rRNA from the A549 cells that
had been either transfected with polyribo(I:C) or infected with the
Newcastle disease virus (NDV), whereas no rRNA cleavage was ob-
served in Sendai virus-infected cells (Fig. 1B). In contrast, no rRNA
cleavage was detected in the similarly treated Huh7 (Fig. 1C) and
Huh7.5 cells (data not shown).
In contrast to the results of our immunoblot data, an antibody
had previously been used to detect RNase L in Huh7 and Huh7.5
cells [6]. RNase L was also detected in HepG2 cells via the binding
of radiolabeled 2–5A in a previously published study [21]. To ad-
dress these differences, we measured RNase L transcripts with
real-time PCR. The RNase L transcript was present in much lower
concentrations in these three cell lines than in A549 cells and
was barely detectable after ampliﬁcation (Fig. 1D). These results





Fig. 1. A scarce endogenous expression of RNase L. (A) The indicated human cells were immunoblotted for RNase L at 24 h after IFN-a (1,000 U/ml) treatment. The blot was
also probed for the IFN-inducible MxA and for tubulin as a loading control. (B) A549 cells were transfected with 1 lg/well of polyribo(I:C) or infected with either Sendai virus
(100 HAU/ml) or Newcastle disease virus rNDV-GFP (m.o.i. of 2). Total RNA was extracted at 24 h and separated in 1% agarose gel containing formaldehyde. EtBr-stained 28S
and 18S rRNA are shown, and the cleavage products are indicated with arrowheads. Note that no cleavage was observed in the cells that had been infected with Sendai virus.
(C) No rRNA cleavage was observed in any of the Huh7 cells that had been treated in the same manner as the A549 cells. (D) RNase L mRNA was ampliﬁed and separated on an
agarose gel (Top) and the relative amount was quantiﬁed by real-time PCR as shown in a bar graph (Bottom). (E) Huh7 cells transiently expressing RNase L were transfected at
24 h with polyribo(I:C), and their rRNA was analyzed at the indicated time. Note that rRNA cleavage (arrowheads) was observed in the RNase L-transfected Huh7 cell. A549
cells were used as controls.
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cells is insufﬁcient to induce rRNA cleavage, providing us with an
opportunity to address the function of this enzyme through its ec-
topic expression. For this purpose, the coding sequence of RNase L
was ampliﬁed from A549 cell mRNA and subcloned into an expres-
sion vector with an N-terminal Flag tag. The transient expression of
RNase L caused Huh7 cells to commence rRNA cleavage in few
hours following polyribo(I:C) transfection, whereas no rRNA cleav-
age was observed in the control cells (Fig. 1E). This result indicated
that the ectopically expressed RNase L was activated at this condi-
tion in this cell line.
3.2. The antiviral activity of RNase L against HCV
The overexpression of RNase L in cultured cells has been shown
to inhibit several viruses that are present in these cells [22]. To
investigate the antiviral activity of RNase L against HCV, Huh7 cellsthat had been transfected with the RNase L construct were infected
at 48 h with HCV J6/JFH1 (m.o.i. of 0.1). The viral core and NS5A
proteins and viral RNA were reduced by 50% in 48 h in the cells
that had been transfected with functional RNase L, whereas the
nuclease-defective enzyme (R667A) [23] had no inhibitory effect
on the HCV proteins and RNA (Fig. 2A).
The antiviral effect of RNase L was also demonstrated in HCV
replicon cells. Huh7 cells that had been transfected with the RNA
genome of HCV JFH-1 were further transfected with RNase L.
Northern blot and real-time PCR analyses indicated that viral
RNA was reduced by 50% in the RNase L-transfected cells, com-
pared with either the control cells or cells expressing the nucle-
ase-defective enzyme R667A (Fig. 2B). The concomitant
occurrence of rRNA cleavage in the RNase L-expressing cells sug-
gested that the ectopically expressed enzyme was activated in
the HCV-replicating cells. The antiviral activity of RNase L was also
examined in the cells stably expressing RNase L. In this protocol,
A B
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Fig. 2. The antiviral activity of RNase L against HCV. (A) Huh7 cells transfected with RNase L or the nuclease-defective R667A constructs were infected at 48 h with HCV J6/
JFH-1 (m.o.i. 0.1). Viral NS5A and core proteins were immunoblotted at 48 h. The blot was also probed with anti-Flag antibody for RNase L and for tubulin, which was used as
a loading control. The viral RNA was analyzed by northern blotting with the intensity of bands indicated. The 28S rRNA was used as a loading control. (B) Huh7 cells that had
been transfected with JFH-1 RNA were transfected 4 h later with RNase L. Total RNA was extracted at the indicated time after viral RNA transfection and the rRNA was
analyzed by an agarose gel electrophoresis (shown in middle). Viral RNA was measured in northern blotting (shown in top) and real-time PCR as indicated in a bar graph
(bottom). (C) Huh7 cells transfected with the wild-type RNase L or R667A constructs were maintained for 3 weeks in the medium containing G418 (300 lg/ml). The
polyclonal cells were pooled and electroporated with JFH-1 RNA. At the indicated time, viral NS5A and core proteins were immunoblotted. RNase L expression was conﬁrmed
with Flag antibody with Hsp70 protein used as a loading control. (D) RNase L-expressing polyclonal cells were electroporated with SGR/Luc-JFH-1 and the luciferase activity
was measured at the indicated times in triplicate. The means and SD were shown in a bar.
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structs were maintained in a selective medium and a population
of pooled cells were transfected with the HCV JFH-1 genome.
Immunoblotting indicated that the viral core and NS5A proteins
were reduced by 50% compared to the control cells or cells stably
expressing R667A (Fig. 2C). The inhibitory effect of RNase L was
more evident in reducing the expression of a luciferase reporter
that was encoded in the SGR/Luc-JFH1, a replication-competent
RNA subgenome of JFH-1 (Fig. 2D). In combination, these results
demonstrated the antiviral activity of RNase L against HCV and
suggested that RNase L has been activated in this process.The antiviral potential of RNase L was further examined through
the immunostaining of JFH-1 replicon cells. RNase L and HCV NS5A
displayed amutually exclusive distribution such that few or no cells
co-expressed both proteins, whereas the nuclease-defective RNase
L proteins and NS5A were often found in the same cells (Fig. 3A).
Counting of the immunostained cells in the microscopic ﬁelds indi-
cated that 10% of cells transfected with the wild-type RNase L
were positively stained for NS5A, whereas more than 50% of cells
transfected with each of the three mutant RNase L constructs were
doubly stained (Fig. 3B). Likewise, in the immunoblot for the pro-
tein expression from JFH-1, no inhibitory activity was observed
AB C
Fig. 3. The distributions of RNase L and HCV NS5A. (A) Huh7 cells that had been transfected with JFH-1 RNA were transfected 4 h later with wild-type RNase L or each of the
nuclease-defective constructs. These cells were immunostained at 48 h with anti-NS5A (red) and anti-Flag (green) antibodies and examined under a confocal microscope. The
two images were overlapped with DAPI-stained nuclear images (blue) in the rightmost panels. (B) The number of NS5A-positive cells (indicated with arrowheads) were count
among RNase L-positive cells in 5 randomly set microscopic ﬁelds (40–50 cells in a ﬁeld). The means and SDs of the 5 countings were shown in bars. (C) Huh-7 cells that had
been transfected with JFH-1 RNA were transfected 4 h later with wild-type RNase L or each of the nuclease-defective RNase L constructs. Immunoblotting was performed at
48 h.
160 Y.-C. Kwon et al. / FEBS Letters 587 (2013) 156–164for the three mutants, namely, R462Q, R667A and H672A [24], in
contrast to the wild-type RNase L (Fig. 3C). These results suggestedthat the antiviral effect was conﬁned to the cells that express the
RNase L with intact catalytic activity.
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The activation of RNase L is dependent on 2–5A, which is syn-
thesized by OAS. OAS expression is induced by IFN-a, but its acti-
vation requires dsRNA. Because our results demonstrating the
rRNA cleavage in HCV replicon cells and in polyribo(I:C)-treated
Huh7 cells that overexpressed RNase L suggested the activation
of this RNase L, and thus the presence and activation of OAS, we
sought to examine the expression of OAS and to assess its antiviral
role against HCV in the studied cell lines.
In humans, OAS comprises a family of enzymes that are en-
coded by three closely related and linked genes, namely, OAS1,
OAS2 and OAS3; these genes contain one, two and three repeats,
respectively, of the basic OAS units. Moreover, several isoforms
are produced from alternatively spliced transcripts of each OAS
gene; in particular, there exist p42 and p46 isoforms of OAS1;
p69 and p71 isoforms of OAS2; and p100 isoform of OAS3. These
various OAS proteins differ in their enzymatic activities, levels of
expression, and subcellular localization, and these differences
could contribute to different antiviral potentials for each OAS iso-
form against speciﬁc viruses. In addition to the aforementioned
OAS genes, an OAS-like (OASL) gene that encodes a catalytically
inactive protein also exists [25].
Although OAS expression is considered to be inducible by IFN,
cell lines vary in their endogenous and IFN-inducible expression
levels of OAS [3]. We found that OAS1 and OAS3 transcripts were
constitutively expressed in Huh7 cells (and A549 cells) and were
signiﬁcantly induced following IFN treatment, whereas OAS2 tran-
scripts were not detectable in the absence of IFN treatment. Impor-
tantly, the levels of the OAS transcripts of JFH-1 replicon cells were
no different from the OAS transcript levels of either the parental
cells or cells that had been transfected with a replication-defective
HCV genome (Fig. 4). These results suggested that no further
induction of OAS occurred in HCV replicon cells and that the
endogenous OAS transcripts that already existed in these cells,
which were presumably the constitutively expressed isoforms of
OAS1 and/or OAS3, might be sufﬁcient to produce the 2–5A that
is required for the activation of RNase L.
3.4. The antiviral activity of OAS1 p46 against HCV
We ﬁrst focused on the OAS1 proteins. A distinctive set of OAS1
isoforms has been reported. Most notably, an SNP (AG/GC vs. AAG/Fig. 4. OAS expression. Transcripts of OAS1, OAS2 and OAS3 were ampliﬁed from
1 lg of RNA that had been extracted from A549 or Huh7 cells before or at 24 h after
IFN-a (1000 U/ml) treatment. This ﬁgure includes ampliﬁed OAS transcripts from
Huh7 cells that had been electroporated with JFH-1 RNA or the replication-
defective (GND) RNA. Note that in contrast to the GND RNA, the JFH-1 RNA was
ampliﬁed. GAPDH mRNA was ampliﬁed as a control. The ampliﬁed DNA was
separated in a 1% agarose gel.C) at the splicing acceptor site of the exon 7 has been attributed to
the expression of the splicing variants p52 from the A allele (due
to the shift of splice-acceptor site one base downstream) and p48
(produced if a splicing acceptor site further downstream is used) in-
stead of p46which is produced from a normally spliced transcript of
G allele. The smallest isoform p42 is commonly produced from both
of these alleles (Supplementary data Fig. S1A). The G allele is known
to be associated with higher enzyme activity, whereas the more
common A allele is associated with lower enzyme activity [26]. It
is particularly noteworthy that patients with the homozygous GG
genotype demonstrated a higher response to interferon therapy
againstHCV infection,whereas theAAgenotypewasassociatedwith
non-response to interferon and higher degrees of liver ﬁbrosis [27].
We found by genomic sequence analysis that Huh7 cell line pos-
sesses the AA genotype and conﬁrmed by RT-PCR the expression
of the splicing variants coding for p42, p48 and p52, respectively,
but no expression of p46 transcript (Supplementary data Fig. S1B).
To assess the antiviral potential of each OAS1 isoform, we sub-
cloned cDNA for the OAS1 isoforms and examined their antiviral
activity. The p46 cDNA was subcloned from human ﬁbrosarcoma
HT1080 cell because it was not present in Huh7 or A549 cells
due to their being AA genotype. Although p46 was not expressed
in Huh7 cells, it was included in our analysis because it is expected
to be present in human liver cells of GG or GA genotype. Interest-
ingly, the expression of p46 showed a notable inhibition for the
protein expression from HCV JFH-1 in an RNase L-dependent man-
ner, whereas no inhibitory effect was produced by the p42, p48 or
p52 isoforms of OAS1 (Fig. 5A). The antiviral activity of p46 was as-
sessed more quantitatively against SGR/Luc-JFH1. The reporter
expression was reduced by up to 40% in the Huh7 cells that were
co-transfected with RNase L and p46 but no other OAS1 isoforms
(Fig. 5B). To rule out the possibility that the different inhibitory ef-
fect might be caused by the different level of expression (as seen in
the immunoblot Fig. 5A), we repeated the inhibition assays with
various amount of transfected DNA for each OAS1 isoforms. A 2-
to 4-fold increase in the amount of transfected DNA of p42, p48
and p52, respectively, showed no stimulation on RNase L, whereas
p46 showed a DNA dose-responsive inhibitory effect on HCV (Data
not shown). These data clearly demonstrated the antiviral activity
of OAS1 p46. However, the functional integrity of OAS activity in
Huh7 cells that we observed without OAS overexpression could
not be explained because this cell line lacks p46.
3.5. The antiviral role of OAS3 p100
Because our OAS mRNA analysis indicated the constitutive
expression of OAS1 and OAS3, we next focused on OAS3. As we
did for OAS1 isoforms, we examined the effect of OAS3 p100 over-
expression on the expression of the transfected HCV JFH-1 genome.
Despite being poorly expressed in this protocol, OAS3 p100 expres-
sion resulted in a notable reduction in the expression of JFH-1 pro-
teins (Fig. 5C) and that of a subgenomic replicon (Fig. 5D) in an
RNase L-dependent manner. This result was contrasted with no ef-
fect seen by the expression of OAS2 p69 or that of OAS2 p71 iso-
forms. We attempted to reduce the expression of OAS1 or OAS3
speciﬁcally through the transfection of synthetic siRNA. Whereas
the RNase L-mediated inhibition against HCV JFH-1was not rescued
by OAS1-speciﬁc siRNA (Fig. 6A), this inhibition was signiﬁcantly
reversed by an OAS3 siRNA (Fig. 6B). This result suggested that at
least in Huh7 cells, OAS3 p100 plays an important role against HCV.
4. Discussion
It was recently demonstrated that the transfection of Huh7 cells
with 2–5A that had been synthesized in vitro resulted in the inhi-




Fig. 5. The antiviral activity of OAS1 p46 and OAS3 p100. (A, C) Huh7 cells replicating JFH-1 HCV were co-transfected with RNase L and each of OAS1 (p42, p46, p48 or p52),
OAS2 (p69 or p71) or OAS3 p100 constructs. The viral NS5A and core proteins were immunoblotted at 48 h. The blot was also probed with anti-Flag antibody to detect the
RNase L and the OAS. Tubulin was probed as a loading control. (B, D) Huh7 cells replicating the subgenome SGR/Luc-JFH1 were co-transfected with RNase L and each of the
OAS constructs. The resulting luciferase activity was measured in triplicate at 48 h, as shown in a bar graph.
162 Y.-C. Kwon et al. / FEBS Letters 587 (2013) 156–164the antiviral role of endogenous RNase L, our analysis indicated
that the endogenous level of RNase L in this hepatoma cell line is
very low. The additional expression of RNase L enabled us to dem-
onstrate this enzyme’s rRNA cleavage and more importantly, the
antiviral activity against HCV. RNase L most likely has a greater
antiviral effect in human liver, given that this enzyme is known
to be expressed at a higher level in human liver cells than in the
examined hepatoma cells [21].
Our results indicating the anti-HCV activity of p46 but no other
OAS1 isoforms in Huh7 cells suggested that the splicing site alleles
of OAS1 might be implicated in HCV infection. Genetic analyses
have suggested that the A allele of OAS1, which produces p48
and p52 and is associated with a lower OAS activity, is considered
to be a risk factor in humans for infection with another ﬂavivirus,
the West Nile virus [28]. It might be interesting to determine the
potential association of this allele with the outcome of HCV infec-
tions of humans. Another interesting question that also remains
unaddressed is why the isoforms that differ only in their C-termi-
nal regions demonstrate different activities.
Our data, which indicate the functional integrity of OAS in Huh7
cells despite the absence of OAS1 p46 expression in these cells (and
also apparent absence of OAS2 expression), suggested a potential
role of OAS3 against HCV. Earlier studies have established that
OAS3 requires much less dsRNA than the other OAS proteins for
its activation and mainly produces 2–5A in its dimer form [29],which is less active than the other forms of 2–5A for the activation
of RNase L. Despite these in vitro data, increasing evidence has sug-
gested potential antiviral roles for OAS3. For example, the p42 and
p46 of OAS1 and the p100 of OAS3 inhibited Dengue virus in an
RNase L-dependent manner, whereas the other OAS isoforms did
not demonstrate this effect [30]. Our data also suggested the
importance of OAS3 p100 against HCV.
The activation of RNase L without the further induction of OAS
expression, as we have shown in JFH-1 replicon cells, is not unique
to HCV. It was reported that in the coxsackievirus or hepatitis A
virus infection of monkey kidney FRhK-4 cells, RNase L could be
activated with no apparent induction of the OAS1 or OAS2 pro-
teins; in these FRhK-4 experiments, OAS3 was constitutively ex-
pressed at a relatively high level, and this expression level
remained unchanged throughout the infection [31]. It appears
likely that only a small quantity of OAS protein is needed as a cat-
alytic enzyme for the activation of RNase L. Thus, constitutively ex-
pressed OAS1 and/or OAS3 might play a safeguard role through the
activation of RNase L in the early stage of antiviral response against
HCV infection.
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